alamo pharma services

Next Generation Pharmaceutical Commercialization Platform - EVERSANA EVERSANA™ combines the leading global life science services into an integrated, independent and intelligent commercialization platform. With services rooted in the patient experience and spanning global pricing, market access, marketing, patient support, channel distribution, and consulting, we create value for patients, prescribers and payers at all stages of the product lifecycle. To learn more about our work to help clients – ranging from innovative start-ups to established pharmaceutical companies - advance life science services for a healthier world, visit eversana.com.

QPS Holdings, LLC

QPS is a GLP/GCP-compliant contract research organization (CRO) delivering the highest grade of discovery, preclinical, and clinical drug development services. An award-winning leader focused on bioanalytics and clinical trials, QPS is known for proven quality standards, technical expertise, a flexible approach to research, client satisfaction and turnkey laboratories and facilities. We are passionate about our work, creating value for patients and customers while generating opportunities for employees to thrive. Since 1995, it has rapidly expanded from a tiny bioanalysis shop to a full-service CRO with 1100+ employees in the US, Europe, India and Asia. Today, it offers expanded pharmaceutical contract R&D services with special expertise in Neuropharmacology, DMPK, Toxicology, Bioanalysis, Translational Medicine, and Clinical Development. Through continual enhancements in capacities and resources, QPS stands tall in its commitment to deliver superior quality, skilled performance and trusted service to its valued customers.

Celerion

Celerion, a leader in early clinical research, delivers Applied Translational Medicine. Celerion applies our expertise and experience to translating information gained in research discoveries, to knowledge of drug action and effect in humans to support early drug development decisions and the clinical pharmacology labeling of new medicines. With over 50 years of experience and 600 global clinic beds (including 24 in-hospital), Celerion conducts and analyzes First-in-Human, clinical proof-of-concept, cardiovascular safety (TQT, robust QT), ADME and NDA-enabling clinical pharmacology studies. Celerion provides expertise on modeling and simulation, study design, medical writing (protocols and reports), clinical data sciences, biostatistics, and PK/PD analysis as well as small and large molecule bioanalytical assays through clinical drug development. Regulatory, drug development and program management complement Celerion’s service offerings. Our operations are strategically located in: Lincoln, Nebraska (Corporate Headquarters) Philadelphia, Pennsylvania Phoenix, Arizona Belfast, Northern Ireland,UK Zurich, Switzerland Vienna, Austria Richmond, Virginia Montreal, Quebec, Canada For more information, visit: www.celerion.com

dohmen life science services

Dohmen Life Science Services is now EVERSANA. EVERSANA™ combines the leading global life science services into an integrated, independent and intelligent commercialization platform. With services rooted in the patient experience and spanning global pricing, market access, marketing, patient support, channel distribution, and consulting, we create value for patients, prescribers and payers at all stages of the product lifecycle. To learn more about our work to help clients – ranging from innovative start-ups to established pharmaceutical companies - advance life science services for a healthier world, visit eversana.com.

Incyte

Incyte is a global biopharmaceutical company focused on finding solutions for serious unmet medical needs through the discovery, development and commercialization of novel medicines. We are committed to the relentless pursuit of science that can improve the lives of patients. Our unique expertise in medicinal chemistry and biology has enabled us to create a diversified portfolio of marketed products and clinical candidates, the majority of which were discovered by Incyte scientists. We are advancing a growing pipeline of medicines across Oncology and Inflammation & AutoImmunity. Headquartered in Wilmington, Delaware, Incyte has more than 2,600 employees and operations in North America, Europe and Asia. We are proud to have been recently recognized by Forbes as one of the World’s Most Innovative Companies. Additionally, Incyte has consecutively been named a Top Employer by Science Magazine, placing #2 on the 2020 list. For more information about Incyte, please visit our corporate website at www.incyte.com and follow us on Twitter: www.twitter.com/incyte. See our Community Guidelines: http://bit.ly/2sV0H5W.